Codexis Announces Three-Year Extension of Collaboration Agreement with Merck
Codexis (NASDAQ: CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, today announced a three-year extension of its catalyst and process development collaboration with Merck to develop enzymes for use in pharmaceutical manufacturing.
As the collaboration enters its sixth year, Merck will continue to use Codexis' proprietary enzyme products to develop more cost- and resource-efficient manufacturing processes for its pipeline of therapeutic candidates. The initial agreement was announced in April 2007 and today's agreement provides an extension to 2015.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.